- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03507543
The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a phase 1, First-In-Human, open label study, trialing a new PARP inhibitor medication IMP4297 in participants with advanced solid tumour.
Six different dosage cohorts 2mg, 6mg, 10mg, 20mg, 30mg and 40mg will be used to establish the maximum tolerated dosage. First participant in each dosing cohort will be administered one dose of IMP4297 capsule, followed by a wash out period of at least 5 half-lives or 7 days. Safety information such as pathology result or adverse events experienced will be collected following first dosing. This will be reviewed by the a safety review committee that is made up of the Principal Investigator, Medical Monitor, the study Sponsor and a representative from the Clinical Research Organisation, which will collectively determine if it is safe to proceed to continue with the next scheduled dosing cohort. Participant will proceed with repeat once daily dose at the same dose level for 3 weeks. Each repeat dose treatment cycle will be composed of 3 weeks (Day 1 to Day 21). IMP4297 will be administered by participants at home. Participants will be instructed to bring unused IMP4297 capsules with them to each visit for trial staff to review and confirm amount of IMP4297capsules taken since the last visit. The administration of the IMP4297 capsules will be recorded. Study drug compliance will be assessed using these records in conjunction with a count of unused IMP4297 capsules. Participants who are benefiting from IMP4297 may have the possibility of treatment beyond 1 year at the investigator's discretion. Participants who experience disease progression or unacceptable side effects, are not compliant with study protocol or in the opinion of the investigator will have IMP4297 administration discontinued and study participation will be terminated.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New South Wales
-
Blacktown, New South Wales, Australia, 2148
- Blacktown Hospital
-
Kogarah, New South Wales, Australia
- St George private Hospital
-
-
Victoria
-
Melbourne, Victoria, Australia, 3004
- Nucleus Network
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed Informed Consent Form
- Age greater than or equal to 18 years
- Histologically or cytologically documented, incurable, advanced solid malignancy that has progressed on, or failed to respond to, at least one prior systemic therapy
- Evaluable or measurable disease per RECIST 1.1
- ECOG performance status of 0 or 1
- In the dose expansion stage, patients with BRCA (breast carcinoma) mutation will be enrolled. Patients with breast cancer, ovarian cancer and prostate cancer are preferred.
Exclusion Criteria:
Inadequate haematologic and organ function, defined by the following (haematologic parameters must be assessed greater than or equal to 14 days after a prior treatment, if any):
- Absolute neutrophil count <1500 cells/uL
- Haemoglobin <9 g/dL
- Total bilirubin >1.5 x the ULN, with documented liver metastases total bilirubin >3 x the ULN .
- AST and/or ALT >2.5 x the ULN, with documented liver metastases AST and/or ALT levels > 5 x the ULN.
- Serum creatinine > 1.5 x the ULN, or creatinine clearance < 50 mL/min based on a documented 24-hour urine collection.
- International normalized ratio (INR) > 1.5 x the ULN or activated partial thromboplastin time (aPTT) >1.5 x the ULN The INR applies only to patients who do not receive therapeutic anti-coagulation.
Any anti-cancer therapy, including chemotherapy, hormonal therapy, biologic therapy, radiotherapy within 4 weeks prior to initiation of study treatment with the following exceptions:
- Hormonal therapy with gonadotropin-releasing hormone (GnRH) agonists for prostate cancer
- Hormone-replacement therapy or oral contraceptives
- Palliative radiation to bone metastases > 2 weeks prior to Day 1
- Adverse events from prior anti-cancer therapy that have not resolved to CTCAE Grade less than or equal to 1, except for alopecia
- Clinical significant active infection
- Known clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
- Known human immunodeficiency virus infection
- New York Heart Association (NYHA) Class II or greater congestive heart failure; history of myocardial infarction or unstable angina within 6 months prior to Day 1; history of stroke or transient ischemic attack within 6 months prior to Day 1
- Active or untreated brain metastasis
- Pregnant (positive pregnancy test) or lactating women
- Male or female patients of child-producing potential unwilling to use double barrier contraception: condoms, sponge, foams, jellies, diaphragm or intrauterine device (IUD), contraceptives (oral, injectable or parenteral), implanon, or other avoidance of pregnancy measures during the study and for 90 days after the last day of treatment
- Inability to take oral medication, prior surgical procedures affecting absorption, or active peptic ulcer disease
- Inability to comply with study and follow-up procedures
- Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the patient at high risk from treatment complications.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: IMP4297
|
The dose levels will be escalated following a modified 3+3 dose escalation scheme.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The AEs (adverse event) of single and multiple doses of IMP4297 administered to participants with advanced solid tumors.
Time Frame: Each visit after IMP4297 administrated (through study completion, an average of 10 months)
|
Evaluate the TEAE (treatment-emergent adverse event) of IMP4297
|
Each visit after IMP4297 administrated (through study completion, an average of 10 months)
|
The maximum tolerated dose (MTD) and evaluate the dose limiting toxicities (DLTs) of IMP4297.
Time Frame: Within 28 days after IMP4297 administrated
|
Evaluate DLT and determine the MTD
|
Within 28 days after IMP4297 administrated
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum plasma concentration (Cmax)
Time Frame: Within 7 days after firstly single dose administrated
|
Within 7 days after firstly single dose administrated
|
Maximum plasma concentration (Cmax)
Time Frame: Within 16 days after first dose administrated in multiple dose cycle 1 (total 21 days in one cycle)
|
Within 16 days after first dose administrated in multiple dose cycle 1 (total 21 days in one cycle)
|
Time at which Cmax occurred (Tmax)
Time Frame: Within 7 days after firstly single dose administrated
|
Within 7 days after firstly single dose administrated
|
Time at which Cmax occurred (Tmax)
Time Frame: Within 16 days after first dose administrated in multiple dose cycle 1 (total 21 days in one cycle)
|
Within 16 days after first dose administrated in multiple dose cycle 1 (total 21 days in one cycle)
|
Trough Concentrations (Ctrough)
Time Frame: Within 7 days after firstly single dose administrated
|
Within 7 days after firstly single dose administrated
|
Trough Concentrations (Ctrough)
Time Frame: Within 16 days after first dose administrated in multiple dose cycle 1 (total 21 days in one cycle)
|
Within 16 days after first dose administrated in multiple dose cycle 1 (total 21 days in one cycle)
|
Clearance (CL/F)
Time Frame: Within 7 days after firstly single dose administrated
|
Within 7 days after firstly single dose administrated
|
Clearance (CL/F)
Time Frame: Within 16 days after first dose administrated in multiple dose cycle 1 (total 21 days in one cycle)
|
Within 16 days after first dose administrated in multiple dose cycle 1 (total 21 days in one cycle)
|
Volume of distribution (Vd/F)
Time Frame: Within 7 days after firstly single dose administrated
|
Within 7 days after firstly single dose administrated
|
Volume of distribution (Vd/F)
Time Frame: Within 16 days after first dose administrated in multiple dose cycle 1 (total 21 days in one cycle)
|
Within 16 days after first dose administrated in multiple dose cycle 1 (total 21 days in one cycle)
|
Area Under Curve [AUClast, AUCINF and AUCtau]
Time Frame: Within 7 days after firstly single dose administrated
|
Within 7 days after firstly single dose administrated
|
Area Under Curve [AUClast, AUCINF and AUCtau]
Time Frame: Within 16 days after first dose administrated in multiple dose cycle 1 (total 21 days in one cycle)
|
Within 16 days after first dose administrated in multiple dose cycle 1 (total 21 days in one cycle)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jason Lickliter, Epworth Medical Centre
- Principal Investigator: Paul Souza, St George private Hospital
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IMP4297-2016-AU01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
Ohio State University Comprehensive Cancer CenterCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Stage III Breast CancerUnited States
Clinical Trials on IMP4297
-
Impact Therapeutics, Inc.Not yet recruiting
-
Impact Therapeutics, Inc.Completed
-
Impact Therapeutics, Inc.Unknown
-
Impact Therapeutics, Inc.Not yet recruiting
-
Impact Therapeutics, Inc.CompletedBreast Cancer | Ovarian Cancer | Prostate Cancer | Advanced Solid TumoursChina
-
Impact Therapeutics, Inc.Completed
-
Impact Therapeutics, Inc.Not yet recruiting
-
Shanghai Junshi Bioscience Co., Ltd.Sponsor GmbHWithdrawnAdvanced Cancer
-
Impact Therapeutics, Inc.RecruitingSmall Cell Lung Cancer | Advanced Solid TumoursTaiwan, Korea, Republic of, China, Australia, United States
-
Impact Therapeutics, Inc.Completed